OpportunityAnalyzer:胰臟癌 - 機會分析與預測
OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017
|出版日期||內容資訊||英文 179 Pages
|OpportunityAnalyzer:胰臟癌 - 機會分析與預測 OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017|
|出版日期: 2014年03月27日||內容資訊: 英文 179 Pages||
With five-year survival only approximately 5%, pancreatic cancer is characterized as a disease with some of the highest unmet need in oncology. This report focuses on the current treatment landscape, unmet needs, pipeline and commercial opportunity in the pancreatic cancer market with coverage of both the early stage resectable and advanced settings. Celgene's Abraxane was launched in the US and Europe in 2013 and 2014, respectively, and was the first drug approved in this disease in nearly a decade. Due to the high unmet need, GlobalData forecasts the rapid uptake of Abraxane, and sales of this drug are expected to drive the overall pancreatic cancer market and are forecast to represent greater than 50% of total market sales in 2017. GlobalData also forecasts the launch of five new pipeline agents into the pancreatic cancer market. Despite the launch of new agents, GlobalData expects significant opportunities to remain for developers of drugs with predictive biomarker-driven strategies. The challenge for new entrants will be to design adequate clinical studies that assess pipeline drugs in carefully selected patient populations and incorporate the current standard-of-care chemotherapies, such as GemAbrax, as backbone regimens. With Big Pharma being actively involved in early-stage innovative projects, GlobalData expects clinical development in pancreatic cancer to accelerate at the end of the forecast period and beyond.